Curcumin nanosystems could be powerful COVID-19 therapeutics

With new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerging, the coronavirus disease 2019 (COVID-19) pandemic is far from over. While the global vaccine rollout has moved at an impressive speed, the search for new safe, effective, and targeted therapies is still on. Now, a new study in Biomedicine and Pharmacotherapy reviews the potential for curcumin, a natural […]

Read more

Long-COVID-19 is a significant risk in recovered patients post-hospitalization

The ongoing coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen, has claimed the lives of over 2.79 million people worldwide. However, the long-term effects of the virus on human health and lifespan are less well known. A new study, which appeared in the British Medical Journal, reports on a retrospective study to […]

Read more

Rare genetic variant may explain severe COVID-19 in young healthy male patients

The novel coronavirus disease 2019 (COVID-19) pandemic has now been spreading for over a year, but several mysteries surrounding its diverse outcomes remain. How is it that some young healthy individuals contract the infection(caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and become critically unwell? Why do others, who are older and have underlying comorbidities, have less severe […]

Read more

Nanoparticles elicit neutralizing antibodies to diverse SARS-CoV-2 variants

Spike-protein-based nanoparticle vaccine candidates were retained longer in follicular dendritic cells and showed higher germinal center reactions in lymph node follicles compared to soluble spike protein vaccine. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected hundreds of millions worldwide since its emergence more than a year ago. The virus has also been mutating throughout the pandemic, with several […]

Read more

Antibody agents effective at neutralizing European, South African, and United States SARS-CoV-2 variants

Researchers in the United States have demonstrated the effectiveness of three antibody agents at neutralizing recently emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the coronavirus disease 2019 (COVID-19) pandemic. The team showed that one full-length antibody and two antibody domains each effectively neutralized pseudotyped virus containing key mutations found within the B.1.1.7 […]

Read more

New covalent and non-covalent SARS-CoV-2 inhibitors discovered in silico

With the onset of the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it came to light that there were no specific and highly effective preventive or therapeutic agents against this virus. The result has been an enormous amount of studies reporting the efficacy or otherwise of novel drug candidates or repurposed drugs […]

Read more

Delaying second dose of Pfizer-BioNTech SARS-CoV-2 vaccine may be feasible in some cases

Researchers in Spain have conducted the most extensive study to date investigating the effectiveness of vaccinating healthcare workers with a single dose of the Pfizer-BioNTech vaccine to protect against coronavirus disease 2019 (COVID-19). The team says one dose of the vaccine induced a much stronger antibody response against the causative agent – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – […]

Read more

Is a single mRNA COVID-19 vaccine dose enough for recovered individuals?

Millions of people across the globe have been affected by the coronavirus disease 2019 (COVID-19) pandemic. Worldwide, researchers are working extensively to develop vaccines, facemasks, viral disinfectants, nasals sprays, and oral medicines to stop the spread of the respiratory pathogen, severe acute respiratory coronavirus 2 (SARS-CoV-2). Study: First dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in […]

Read more

Is a single mRNA COVID-19 vaccine dose enough for recovered individuals?

Millions of people across the globe have been affected by the coronavirus disease 2019 (COVID-19) pandemic. Worldwide, researchers are working extensively to develop vaccines, facemasks, viral disinfectants, nasals sprays, and oral medicines to stop the spread of the respiratory pathogen, severe acute respiratory coronavirus 2 (SARS-CoV-2). Study: First dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in […]

Read more

Research demonstrates multivalent nanobodies overcome SARS-CoV-2 variant mutations

Since the start of the COVID-19 (coronavirus disease 2019) pandemic in late December 2019, the etiological agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) of this disease has caused more than 2.6 million deaths worldwide from over 117 million reported infections. However, as new vaccines are administered against the ancestral strain, many mutated variants of the virus are emerging across […]

Read more
1 2 3